AVIDA The Vidaza® (Azacitidine) Patient Registry

This registry is a prospective, multi-center, observational study compiling data on the natural history and management of patients receiving Vidaza, and will provide unique insights into the management of myelodysplastic syndromes (MDS) and other hematological disorders and the impact of these disorders on patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Myelodysplastic Syndromes Bone Marrow Diseases Hematologic Diseases Hemic and Lymphatic Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

AVIDA Registry Help

Kansas City, Missouri, 66210, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patient who is deemed appropriate for treatment with Vidaza® by his or her clinician, but who has not already started receiving Vidaza® treatment.
Patient who is able to read and speak English.
Patient who is willing and able to provide informed consent.
Patient who agrees to complete patient assessment questionnaires.

Exclusion criteria

Patients who are currently being treated with Vidaza®.
Patients who are concurrently participating in a clinical trial.
Patients unwilling or unable to complete the baseline and follow-up questionnaires.
Patients who are deemed inappropriate for treatment with Vidaza®.

Treatment and study plan

Azacitidine

Drug

Physician's discretion

Other names: Vidaza(R)

Primary outcomes

Vidaza usage

Time frame: Approximately 4 years

Describe current usage patterns for Vidaza in the community
Concomitant care and treatment

Time frame: Approximately 4 years

Document common concomitant care procedures and treatments used in conjnction wtih Vidaza
Duration and number of cycles

Time frame: Approximately 4 years

Correlate duration and number of Vidaza treatment cycles with clinical response as defined by 2006 International Working Group for Myeleodysplastic Syndrome
Publication

Time frame: Approximately 4 years

Produce publications to support further clinical development and disseminate information on treatment best practices

Sponsors and collaborators

Lead sponsor

Celgene

Industry

Registry information

Acronym: AVIDA

Important dates

Study start: 2006
Primary completion: 2010
Study completion: 2010
First posted: Jun 1, 2007
Registry last updated: May 3, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed